Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval

Deep News03-03

On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of advanced prostate cancer. According to the news release, GLR2037 tablets are a Class 1 chemical new drug independently developed by the company, functioning as a bispecific protein degradation therapy targeting the androgen receptor (AR). Bispecific protein degradation therapy is an emerging treatment approach that utilizes the cell's natural protein degradation mechanism, known as the ubiquitin-proteasome system (UPS), to selectively target and degrade disease-related proteins. This method potentially allows for the modulation of traditionally "undruggable" targets that are difficult to address with conventional small molecules. As an innovative drug product with novel technology and structure developed independently by Gan & Lee Pharmaceuticals, GLR2037 tablets are expected to provide new treatment options for patients with advanced prostate cancer who have developed resistance to AR-targeting drugs, potentially extending patient survival.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169160645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169160645","market":"hk","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval","media":"Deep News","content":"<p>On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of advanced prostate cancer. According to the news release, GLR2037 tablets are a Class 1 chemical new drug independently developed by the company, functioning as a bispecific protein degradation therapy targeting the androgen receptor (AR). Bispecific protein degradation therapy is an emerging treatment approach that utilizes the cell's natural protein degradation mechanism, known as the ubiquitin-proteasome system (UPS), to selectively target and degrade disease-related proteins. This method potentially allows for the modulation of traditionally \"undruggable\" targets that are difficult to address with conventional small molecules. As an innovative drug product with novel technology and structure developed independently by Gan & Lee Pharmaceuticals, GLR2037 tablets are expected to provide new treatment options for patients with advanced prostate cancer who have developed resistance to AR-targeting drugs, potentially extending patient survival.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-03 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of advanced prostate cancer. According to the news release, GLR2037 tablets are a Class 1 chemical new drug independently developed by the company, functioning as a bispecific protein degradation therapy targeting the androgen receptor (AR). Bispecific protein degradation therapy is an emerging treatment approach that utilizes the cell's natural protein degradation mechanism, known as the ubiquitin-proteasome system (UPS), to selectively target and degrade disease-related proteins. This method potentially allows for the modulation of traditionally \"undruggable\" targets that are difficult to address with conventional small molecules. As an innovative drug product with novel technology and structure developed independently by Gan & Lee Pharmaceuticals, GLR2037 tablets are expected to provide new treatment options for patients with advanced prostate cancer who have developed resistance to AR-targeting drugs, potentially extending patient survival.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603087","symbol_name":"甘李药业","start_time":0,"source_url":"","article_id":"1169160645","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169160645","pubTimestamp":1772515309,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"甘李药业新型靶向蛋白降解疗法获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":1},"content_text":"On March 2, Gan & Lee Pharmaceuticals announced that its investigational drug, GLR2037 tablets, has obtained implicit approval for clinical trials, with proposed development for the treatment of advanced prostate cancer. According to the news release, GLR2037 tablets are a Class 1 chemical new drug independently developed by the company, functioning as a bispecific protein degradation therapy targeting the androgen receptor (AR). Bispecific protein degradation therapy is an emerging treatment approach that utilizes the cell's natural protein degradation mechanism, known as the ubiquitin-proteasome system (UPS), to selectively target and degrade disease-related proteins. This method potentially allows for the modulation of traditionally \"undruggable\" targets that are difficult to address with conventional small molecules. As an innovative drug product with novel technology and structure developed independently by Gan & Lee Pharmaceuticals, GLR2037 tablets are expected to provide new treatment options for patients with advanced prostate cancer who have developed resistance to AR-targeting drugs, potentially extending patient survival.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169160645","isCrawlerRequest":true}